In fact, those breast cancer patients who develop NAFLD on anti-estrogen have better disease free survival and overall survival compared to those without NAFLD, suggesting that this type of drug-induced NAFLD is strongly correlated to target engagement by anti-estrogen on ERα 24. Here, ESR1 is linked to metabolic dysfunction-associated steatotic liver disease.